How can we help you be the first biotech in a decade to IPO on the NASDAQ?
With the opening of the biotech IPO window in the US in 2013, long-standing client Prosensa decided to list on NASDAQ during June with an indicated share price range of $11-$13 and the issue of 5 million shares. It would be the first biotech to do so in 10 years and it paved the way for many others to follow. Our goal was to ensure that all communications materials and strategies were up date in line with its listed status.
Having built a profile for Prosensa as a leading biotech company and a leader in the rare diseases and Duchenne Muscular Dystrophy (DMD) space we ensured that all public materials such as website and presentations reflected the messaging in the prospectus. On impact day we supported Prosensa with media interviews and follow-up. We continued our support, updating strategy and messaging, addressing a number value catalysts and strategic news through to the successful sale of the company to BioMarin in late 2015.
Around the IPO we secured on-message coverage in The New York Times, Dow Jones, Fierce Biotech, BioCentury, Scrip and The Sunday Times among others. During our five years of supporting Prosensa’s communications campaigns it achieved a number of accolades, winning Mediscience emerging star in the year prior to its IPO and BioCapital and Scrip Biotech company of the year in 2015.